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AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Moderate to vigorous physical activity (MVPA) is strongly associated with risk reductions of
noncommunicable diseases and mortality. Cardiovascular health status may influence the
benefits of MVPA. We compare the association between MVPA and incident major adverse
cardiovascular events (MACE) and mortality between healthy individuals, individuals with
elevated levels of cardiovascular risk factors (CVRF), and cardiovascular disease (CVD).
Methods and findings
A cohort study was performed in the 3 northern provinces of the Netherlands, in which data
were collected between 2006 and 2018, with a median follow-up of 6.8 years (Q25 5.7; Q75
7.9). A total of 142,493 participants of the Lifelines Cohort Study were stratified at baseline
as (1) healthy; (2) CVRF; or (3) CVD. Individuals were categorized into “inactive” and 4 quar-
tiles of least (Q1) to most (Q4) active based on self-reported MVPA volumes. Primary out-
come was a composite of incident MACE and all-cause mortality during follow-up. Cox
regression was used to estimate hazard ratios (HRs), 95% confidence intervals (CIs) and P
values. The main analyses were stratified on baseline health status and adjusted for age,
sex, income, education, alcohol consumption, smoking, protein, fat and carbohydrate
intake, kidney function, arrhythmias, hypothyroid, lung disease, osteoarthritis, and rheuma-
toid arthritis. The event rates were 2.2% in healthy individuals (n = 2,485 of n = 112,018),
7.9% in those with CVRF (n = 2,214 of n = 27,982) and 40.9% in those with CVD (n = 1,019
of n = 2,493). No linear association between MVPA and all-cause mortality or MACE was
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found for healthy individuals (P = 0.36) and individuals with CVRF (P = 0.86), but a linear
association was demonstrated for individuals with CVD (P = 0.04). Adjusted HRs in healthy
individuals were 0.81 (95% CI 0.64 to 1.02, P = 0.07), 0.71 (95% CI 0.56 to 0.89, P = 0.004),
0.72 (95% CI 0.57 to 0.91, P = 0.006), and 0.76 (95% CI 0.60 to 0.96, P = 0.02) for MVPA
Q1 to Q4, respectively, compared to inactive individuals. In individuals with CVRF, HRs
were 0.69 (95% CI 0.57 to 0.82, P < 0.001), 0.66 (95% CI 0.55 to 0.80, P < 0.001), 0.64
(95% CI 0.53 to 0.77, P < 0.001), and 0.69 (95% CI 0.57 to 0.84, P < 0.001) for MVPA Q1 to
Q4, respectively, compared to inactive individuals. Finally, HRs for MVPA Q1 to Q4 com-
pared to inactive individuals were 0.80 (95% CI 0.62 to 1.03, P = 0.09), 0.82 (95% CI 0.63 to
1.06, P = 0.13), 0.74 (95% CI 0.57 to 0.95, P = 0.02), and 0.70 (95% CI 0.53 to 0.93, P =
0.01) in CVD patients. Leisure MVPA was associated with the most health benefits, nonlei-
sure MVPA with little health benefits, and occupational MVPA with no health benefits. Study
limitations include its observational nature, self-report data about MVPA, and potentially
residual confounding despite extensive adjustment for lifestyle risk factors and health-
related factors.
Conclusions
MVPA is beneficial for reducing adverse outcomes, but the shape of the association
depends on cardiovascular health status. A curvilinear association was found in healthy and
CVRF individuals with a steep risk reduction at low to moderate MVPA volumes and benefits
plateauing at high(er) MVPA volumes. CVD patients demonstrated a linear association, sug-
gesting a constant reduction of risk with higher volumes of MVPA. Therefore, individuals
with CVDs should be encouraged that “more is better” regarding MVPA. These findings may
help to optimize exercise prescription to gain maximal benefits of a physically active
lifestyle.
Author summary
Why was this study done?
• There is debate to whether cardiovascular health status affects the dose–response associ-
ation between physical activity (PA) and health outcomes.
• Studies among cardiovascular diseases (CVDs) patients found different associations
between PA and mortality reductions, which were described as linear, J shaped, or U
shaped.
• Recent studies suggested that the cardiovascular health benefits or risk of death of PA
may be domain specific as different outcomes were reported for leisure versus occupa-
tional PA.
What did the researchers do and find?
• A cohort study (median follow-up 6.8 years) was performed comparing the association
between moderate to vigorous physical activity (MVPA) and incident major adverse
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cardiovascular events (MACE) and all-cause mortality between healthy individuals (n =
112,018), individuals with cardiovascular risk factors (CVRF) (n = 27,982), and CVD (n
= 2,493).
• The shape of dose–response association between MVPA and cardiovascular events and
death is curvilinear for healthy individuals and those with CVRF, whereas a linear rela-
tionship was found in individuals with CVDs.
• The association between MVPA and the risk of CVD or mortality is domain specific as
leisure activities were associated with the most benefits, nonleisure activities with little
benefits, and occupational activities with no benefits.
What do these findings mean?
• MVPA is associated with risk reductions in all groups, but, especially, CVD patients
should be encouraged that “more is better” regarding PA.
• PA recommendations could be optimized by taking cardiovascular health status and the
domain of MVPA into account.
Introduction
Regular physical activity (PA) is strongly associated with risk reductions of noncommunicable
diseases and mortality [1,2]. The 2020 World Health Organization Physical Activity Guidelines
recommend adults to perform at least 150 minutes/week of moderate intensity PA, or 75 min-
utes/week of vigorous intensity PA, or an equivalent combination of the 2. It also states that
individuals with chronic diseases should not follow a “one-size-fits-all” approach and may
benefit from alternative exercise prescription. This is especially relevant, given the debate as to
whether health status affects the dose–response association between PA and event rate [1,3].
Data from the general population indicate that the benefits of PA on mortality and morbid-
ity follow a curvilinear dose–response relationship [1,3–5], indicating that low or moderate
volumes of PA yield a large risk reduction, whereas further increases in exercise volumes pro-
duce smaller additional benefits. By contrast, studies among cardiovascular disease (CVD)
patients show conflicting results. Some studies found a linear association between PA and
mortality reductions [6–8], whereas others support the presence of a reverse J-shaped or U-
shaped relationship [9–12]. An important limitation of these studies is the inclusion of a single
group only, with no study directly comparing the PA dose–response relationship among indi-
viduals with different cardiovascular health status.
The present study compared the association between the dose of moderate to vigorous
(MV) PA and major adverse cardiovascular events (MACE) and all-cause mortality across
healthy individuals, individuals with elevated levels of cardiovascular risk factors (CVRF), and
individuals with CVD. We also examined the association of the specific domains of accumulat-
ing moderate to vigorous physical activity (MVPA), including leisure, nonleisure, and occupa-
tional activities on the outcomes, as recent studies suggested that the PA health benefits may
differ across the domain in which PA was performed [13]. We hypothesized that the inverse
curvilinear relationship between MVPA volumes and the risk of adverse outcomes, such as
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This study used prospectively gathered data from the Lifelines Cohort Study, a multidisciplin-
ary, population-based cohort of 167,729 individuals living in the northern part of the Nether-
lands. Lifelines uses a broad range of procedures to assess the biomedical, sociodemographic,
behavioral, physical, and psychological factors that contribute to health and disease [14,15]. All
inhabitants of the northern Netherlands were eligible for Lifelines except for individuals with
(1) severe psychiatric or physical illness (e.g., including individuals with cancer and associated
reduced life expectancy); (2) life expectancy <5 years; and (3) lack of fluency in Dutch. Partici-
pants�18 years old (n = 152,739) were included. Participants were excluded from analyses
when (1) no PA data were available (n = 8,666); (2) the participant had an amputated foot or
leg (n = 165); or (3) the participant had a disease influencing their ability to be physically
active, including multiple sclerosis (n = 347) and Parkinson disease (n = 76) (S1 Fig). We used
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guide-
line (S1 Table) to report our findings. Participants provided written informed consent as
approved by the University Medical Center Groningen Medical Ethical Committee.
Physical examination and questionnaire
Participants received a physical examination and completed a baseline questionnaire between
2006 and 2013. The physical examination included anthropometric and blood pressure (BP)
measurements. Resting systolic and diastolic BP was based on the average of 10 measurements
obtained over 10 minutes using an automated sphygmomanometer (Dynamap, PRO 100V2).
Blood samples were obtained after >8 hour of fasting for measurement of total, high-density
lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol, triglycerides, and serum
creatinine. Renal function (estimated glomerular filtration rate, eAU : PleasenotethateGFRhasbeendefinedasestimatedglomerularfiltrationrateinthesentenceRenalfunctionðestimatedglomerularfiltrationrate; eGFRÞwas::::Pleasecheckandcorrectifnecessary:GFR) was estimated [16].
Questionnaires obtained general, lifestyle, and medical data. General information included
age, sex, postal code, education level, and income. Income was estimated from Statistics Neth-
erlands [17] using postal codes when not reported. Lifestyle factors included smoking status,
alcohol consumption, nutrition intake, and hours of sleep per night. High alcohol consump-
tion was defined as>14 drinks/week or >4 drinks/day for men and>7 drinks/week or >3
drinks/day for women [18]. Smoking status was categorized as currently, previously, and
never. Dietary caloric (kcal), protein (g/day), fat (g/day), and carbohydrate (g/day)) intake
were assessed using a food frequency questionnaire (FFQ) [19]. Total calories (kcal) and pro-
tein, fat, and carbohydrates intake (grams/day) were calculated from the FFQ. The medical his-
tory included medication use, presence of CVD, comorbidities, and other illnesses, including
cancer, arthritis, multiple sclerosis, and Parkinson disease. Details on the physical examination
and questionnaires are described elsewhere [14,15].
Habitual PA volumes
Baseline PA was assessed using the Short Questionnaire to Assess Health-enhancing Physical
Activity (SQUASH) [20]. SQUASH is divided into transportation, occupation, household, and
leisure domains and asks for the duration and intensity of an individual’s typical weekly activi-
ties over the past 3 months. Weekly physical activities were converted to the average amount
of metabolic equivalent of task (MET) minutes per week based on the compendium of physical
PLOS MEDICINE Association between moderate to vigorous physical activity and adverse outcomes
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activities [21]. MET minutes were calculated by multiplying the MET values of each activity by
the duration. Only activities with an MV (� 3 MET) intensity were included, since these activ-
ities are specified in the PA guidelines [22]. Leisure MVPA contained all activities performed
during leisure time. Nonleisure MVPA was defined as PA during transportation, occupation
(i.e., intense work activities) and household activities. Subanalyses for occupational MVPA
were performed, since previous studies suggest a potential harmful health effect of occupa-
tional PA [13]. Total and domain-specific MVPA was used to categorize individuals as inactive
individuals (0 MET min/week of MVPA) and into quartiles of MVPA volumes (>0 MET min/
week; Q1 to Q4).
Health status
Participants were divided at baseline into (1) healthy; (2) CVRF; or (3) CVD. Healthy individu-
als had CVRF (i.e., BP, cholesterol and glucose) within the normal range and did not have
known CVD. Individuals with CVRF had at least 1 of the following at baseline: (1) self-reported
hypertension, hypercholesterolemia, or diabetes and used BP-lowering, cholesterol-lowering, or
diabetic medications; or (2) had cholesterol levels�6.5 mmol/L or glucose levels>6.9 mmol/L
fasting or>11.0 mmol/L nonfasting [23,24]; and (3) did not reported CVD. Individuals with
CVD reported a history of heart failure, myocardial infarction, or stroke and used cardiovascu-
lar medication for these conditions at baseline. The classification of the 3 health status groups
was mutually exclusive, meaning the participants were classified into one group.
Clinical outcomes
The primary end point was a composite of overall adverse events including MACE and all-
cause mortality including CVD mortality. Secondary outcomes were (1) all-cause mortality;
and (2) a composite of CVD mortality and MACE. The national death and hospital registry of
Statistics Netherlands were used to determine the primary and secondary outcomes. CVD
mortality was based on the International Statistical Classification of Disease and Related
Health Problems 10th Revision (ICD-10) [25] and included heart, essential hypertension,
hypertensive renal, and cerebrovascular diseases deaths (I00 to I78) [25]. MACE was defined
as SAU : PleasedefineSTatfirstmentioninthesentenceMACEwasdefinedasST   elevatedmyocardial:::ifapplicable=appropriateandaddtothemainabbreviationlist:T-elevat d myocardial infarct, non-ST–el vated myocardial infarction, stroke, chronic
heart failure, acute heart failure, and major cardiothoracic interventions such as coronary
artery bypass grafting, acute and elective percutaneous coronary intervention, and heart trans-
plantation. MACE was classified using the diagnosis treatment codes of the insurance claims
from the hospital registry of Statistics Netherlands. When hospital registry data were not avail-
able, self-reported MACE during follow-up were used instead. Self-reported MACE was
assessed using follow-up questionnaires filled in after a median follow-up of 1.1, 2.1, and 3.8
years. For the date of the self-reported MACE event, we used the date at which the question-
naire was completed. Participants were followed until the first MACE event or death, which-
ever occurred first. Participants who did not reach the end point were censored at the end of
the last assessment.
Statistical analyses
Baseline characteristics were described for each group by cardiovascular health status. Nor-
mally distributed data were presented with mean (± standard deviation; SD), and non-nor-
mally distributed data with the median [interquartile range; Q25 to Q75]. For categories, the
frequency with percentages were used to describe the data. To compare the differences
between the 3 groups at baseline, 1-way independent analysis of variance (ANOVA), Kruskal–
Wallis tests, and χ2 tests were performed.
PLOS MEDICINE Association between moderate to vigorous physical activity and adverse outcomes
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Stratified Kaplan–Meier curves and log-rank tests were conducted to assess differences in
outcomes between physically inactive and active individuals. The crude and adjusted hazard
ratios (HRs) with 95% confidence intervals (CIs) were calculated using univariable and multi-
variable Cox proportional hazards modeling. Separate models were fitted for those with and
without CVRF or CVD. Model 1 was adjusted for age (years) and sex (male/female). Model 2
was further adjusted for income (per 1,000 euros), education (low/moderate/high), alcohol
consumption (low/high), smoking (pack years), protein (g/day), fat (g/day) and carbohydrate
(g/day) intake, kidney function (mL/min/1.73 m2), arrhythmias (yes/no), hypothyroid (yes/
no), lung disease (yes/no), osteoarthritis (yes/no), and rheumatoid arthritis (yes/no). Model 3
was further adjusted for factors within the causal pathway for CVD: glucose (mmol/L), total
cholesterol (mmol/L), diastolic (mm Hg) and systolic BP (mm Hg), body mass index (BMI;
(kg/m2)), and sleep (hours). Adjustment for covariates were similar for total, nonleisure, and
occupational MVPA, but nonleisure MVPA was added to model 2 while examining the associ-
ation between leisure MVPA and outcome. To investigate whether the dose–response relation-
ship was moderated by cardiovascular health status, we tested interaction terms of health
status (healthy, CVRF, and CVD) and the 5 MVPA categories (i.e., inactive group and quartiles
of MVPA). In addition, to examine the shape of the dose–response associations between
MVPA and the primary outcome, we performed restricted cubic spline regression analyses.
We tested 3 (knots location at 0.10, 0.50, and 0.90 percentile), 4 (knots location at 0.05, 0.35,
0.65, and 0.95 percentile), and 5 knots (knots location at 0.05, 0.275, 0.50, 0.725, and 0.95 per-
centile) and calculated the Akaike information criterion to identify the best fit model [26].
Missing data of covariates were imputed with multiple imputations by chained equations
with predictive mean matching [27] since 14% (n = 20,321) of the individuals had missing data
for one of the covariates used in the model adjustments. We checked patterns of missing data
and followed the “missing at random” assumption. All available variables were used to predict
missing values in 5 imputed datasets with 20 iterations. Healthy convergence, imputed distri-
bution, and plausibility were verified.
Sensitivity analyses were performed to assess the potential presence of reverse causation
bias and the effect of the age difference between the 3 groups. For this purpose, we excluded
participants who experienced an event and/or were censored within 2 years of follow-up, and
we restricted the analyses to participants with an age above 50 years. Furthermore, effect modi-
fication (i.e., interaction terms and stratified analyses) was tested for age, sex, and education.
All statistical analyses were performed in R version 3.5.2 using the following packages: survival




A total of 143,483 participants were evaluated for inclusion, of which 990 were excluded, leav-
ing 142,493 participants available for analyses (S1 Fig). Mean age (42 years [SD 12)), propor-
tion of males (40%), and BMI (25 [Q25 23 to Q75 28] were lower in the healthy individuals than
in those with CVRF (54 years [SD 11], 45% male, BMI 27 [Q25 25, Q75 30]) or those with CVD
(60 years [SD 11], 65% male, BMI 28 [Q25 25, Q75 31]) (Table 1). Healthy individuals were
more often current smokers, had lower systolic and diastolic BP and triglycerides, higher
HDL, lower serum creatinine, and fewer comorbidities. MVPA volumes were highest in
healthy individuals (3,666 MET min/week [Q25 1,825; Q75 7,344]), followed by individuals
with CVRF (3,420 MET min/week [Q25 1,674; Q75 6,567]) and CVD (3,333 MET min/week
[Q25 1,460; Q75 6,093]). MVPA was mostly performed during leisure time in all 3 groups. The
PLOS MEDICINE Association between moderate to vigorous physical activity and adverse outcomes
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Table 1. Baseline characteristics of the study population stratified by health status.
General characteristics Healthy individuals N = 112,018 Individuals with CVRF N = 27,982 Individuals with CVD N = 2,493
Sex (male) 44,924 (40%) 12,561 (45%) 1.620 (65%)
Age (years) 42 (12) 54 (11) 60 (11)









































































Antiplatelet 94 (0%) 83 (0%) 136 (6%)
Antihypertensive 211 (0%) 7,364 (26%) 1,130 (45%)
Anticoagulant 335 (0%) 424 (2%) 279 (11%)
Acetylsalicylic 731 (1%) 1,660 (6%) 1,621 (65%)
Anti-arrhythmic 244 (0%) 343 (1%) 113 (5%)
Beta-blocker 1,066 (1%) 5,271 (19%) 1,137 (46%)
Calcium antagonist 291 (0%) 1,956 (7%) 417 (17%)
Diuretics 213 (0%) 4,650 (17%) 499 (20%)
Statins 204 (0%) 6,126 (22%) 1,454 (58%)
Alternative cholesterol-lowering medication 6 (0%) 305 (1%) 114 (5%)
Antidiabetics 0 (0%) 2,121 (8%) 200 (8%)
Confirmed medication for CVD 0 (0%) 0 (0%) 1,881 (75.5%)
Health characteristics
Systolic BP (mm Hg) 123 (14) 133 (16) 130 (17)
Diastolic BP (mm Hg) 73 (9) 77 (10) 74.62 (9)
Total cholesterol (mmol/L) 4.9 (0.8) 5.87 (1.28) 4.56 (1.05)
LDL cholesterol (mmol/L) 3.1 (0.8) 3.89 (1.16) 2.78 (0.95)
HDL cholesterol (mmol/L) 1.5 (0.4) 1.47 (0.43) 1.33 (0.37)
Triglycerides (mmol/L) 0.9 [0.7, 1.3] 1.3 [1.0, 1.9] 1.2 [0.9, 1.7]
Renal function (mL/min/1.73 m2) 99.8 [89.1, 100.0] 90.7 [79.8, 100.0] 85.5 [73.5, 95.5]
Presence of comorbidities
Diabetes 0 (0%) 3,411 (12%) 303 (12%)
Hypertension 0 (0%) 12,300 (44%) 1,258 (51%)
Hypercholesterolemia 0 (0%) 18,004 (65%) 1,278 (51%)
(Continued)
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median percentage of MVPA spent during leisure time was 68% for the healthy, 78% for
CVRF, and 89% for CVD.
Clinical outcomes
During a median follow-up of 6.8 years (Q25 5.7; Q75 7.9), 5,799 participants reached the pri-
mary end point: 1,605 died and 4,194 had a MACE. The event rates were 2.2% in healthy indi-
viduals (2,485 of 112,018), 7.9% in those with CVRF (2,214 of 27,982) and 40.9% in those with
CVD (1,019 of 2,493). Stratified Kaplan–Meier analyses showed a significantly higher event
free survival among the active individuals compared to inactive individuals (Fig 1).
Health benefits of MVPA
There was no linear association between MVPA and the risk of all-cause mortality and MACE
for healthy individuals (HR 0.998 per 500 MET min/week [95% CI 0.993 to 1.00], P = 0.36)
and individuals with CVRF (HR 0.997 per 500 MET min/week [95% CI 0.986 to 1.01],
P = 0.86) (Table 2). However, the linear association between MVPA and health outcomes was
significant for individuals with CVD (HR 0.991 [95%CI 0.983 to 0.999], P = 0.04). Based on
Table 1. (Continued)
General characteristics Healthy individuals N = 112,018 Individuals with CVRF N = 27,982 Individuals with CVD N = 2,493
Arrhythmia 6,098 (5%) 3,566 (13%) 807 (32%)
Hypothyroid 2,741 (2%) 1,307 (5%) 94 (4%)
Lung disease 13,238 (12%) 3,550 (13%) 379 (15%)
Osteoarthritis 6,159 (6%) 4,045 (15%) 432 (17%)
Rheumatoid arthritis 1,890 (2%) 946 (3%) 123 (5%)
Data are presented as mean (SD), median [Q25, Q75], and n (%).
BAU : TheabbreviationlistsofTables1and2havebeenupdated:Pleaseverifythatallentriesarecorrect:MI, body mass index; BP, blo d pressure; CVD, cardiovascular diseas ; CVRF, cardiovascular risk facto ; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
PA, physical activity; MET, metabolic equivalent of task.
https://doi.org/10.1371/journal.pmed.1003845.t001
Fig 1. Unadjusted Kaplan–Meier estimates of all-cause mortality and MACE for quartiles of total MVPA during follow-up stratified for healthy individuals (A),
individuals with elevated levels of CVRF (B), and individuals with CVD (C). Inactive participants had a significantly lower event-free survival compared with
physically active individuals (Q1 to Q4). CAU : AbbreviationlistshavebeencompiledforthoseusedthroughoutFigs1   3:Pleaseverifythatallentriesarecorrect:VD, cardiovascular di e se; CVRF, cardiovascular risk factors; MACE, major advers cardiovascular events; MVPA,
moderate to vigorous physical activity.
https://doi.org/10.1371/journal.pmed.1003845.g001
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the restricted cubic spline regression model, we found statistically significant P values of non-
linearity for healthy individuals and those with CVRF (P = 0.002 and P< 0.001, respectively),
suggesting a nonlinear association between MVPA and MACE and mortality.
Stratified and unadjusted analyses using quartiles of MVPA showed that active individuals
showed a significantly lower risk of all-cause mortality and MACE compared to inactive indi-
viduals (Fig 2, Table 2). After adjustment for confounders (model 2), healthy individuals dem-
onstrated significantly lower HRs within the second (HR 0.71 [95% CI 0.56 to 0.89],
P = 0.004), third (HR 0.72 [95% CI 0.57 to 0.91], P = 0.006), and fourth quartile (HR 0.76 [95%
CI 0.60 to 0.96], P = 0.02) of total MVPA, compared to inactive individuals. Participants with
CVRF had significantly lower HRs within all quartiles of total MVPA (HRs Q1 0.69 [95% CI
0.57 to 0.82], P< 0.001, Q2 0.66 [95% CI 0.55 to 0.80], P< 0.001, Q3 0.64 [95% CI 0.53 to
Table 2. HRs [95% CI] for the adverse outcomes by total MVPA.
Total PA (MET min/week) Primary outcome—All-cause mortality and incident MACE
Unadjusted model Model 1, adjusted
for age and sex
Model 2, adjusted
for confounders�
Model 3, adjusted for confounders
and mediators†
Healthy individuals
Continuous 0.999 [0.999; 0.999] 0.999 [0.999;1.00] 0.999 [0.999;1.00] 1.00 [0.999;1.00]
Continuous per 500 MET min/week 0.994 [0.990; 0.998] 0.998 [0.993;1.00] 0.998 [0.993;1.00] 0.998 [0.994;1.00]
P for linear trend 0.007 0.31 0.36 0.54
Quartiles
Inactive (n = 1,614)
Q1 1 to 1,912 (n = 27,146)
Q2 1,913 to 3,690 (n = 27,518)
Q3 3,690 to 7,257 (n = 27,343)
Q4 >7,527 (n = 28,397)
1
0.47 [0.37; 0.59], P< 0.001
0.41 [0.33; 0.52], P< 0.001
0.46 [0.36; 0.58], P< 0.001
0.42 [0.34; 0.54], P< 0.001
1
0.68 [0.54;0.86], P 0.001
0.57 [0.45;0.72], P < 0.001
0.57 [0.45;0.72], P < 0.001
0.63 [0.50;0.80], P < 0.001
1
0.81 [0.64;1.02], P 0.07
0.71 [0.56;0.89], P 0.004
0.72 [0.57;0.91], P 0.006
0.76 [0.60;0.96], P 0.02
1
0.83 [0.66;1.05], P 0.13
0.73 [0.58;0.93], P 0.01
0.75 [0.60;0.65], P 0.02
0.80 [0.63;1.01], P 0.06
Individuals with CVRF
Continuous 0.999 [0.999; 0.999] 0.999 [0.999; 1.00] 0.999 [0.999; 1.00] 1.00 [0.999; 1.00]
Continuous per 500 MET min/week 0.987 [0.978; 0.998] 0.993 [0.998; 1.00] 0.997 [0.986; 1.01] 0.998 [0.987; 1.01]
P for linear trend 0.004 0.44 0.86 0.73
Quartiles
Inactive (n = 860)
Q1 1 to 1,912 (n = 7,154)
Q2 1,913 to 3,690 (n = 6,846)
Q3 3,690 to 7,257 (n = 7,016)
Q4 >7,527 (n = 6,106)
1
0.50 [0.41; 0.60], P< 0.001
0.46 [0.38; 0.55], P< 0.001
0.48 [0.40; 0.58], P< 0.001
0.44 [0.36; 0.53], P< 0.001
1
0.65 [0.54;0.79], P < 0.001
0.60 [0.50;0.73], P < 0.001
0.58 [0.48;0.70], P < 0.001
0.63 [0.52;0.76], P < 0.001
1
0.69 [0.57;0.82], P < 0.001
0.66 [0.55;0.80], P < 0.001
0.64 [0.53;0.77], P < 0.001
0.69 [0.57;0.84], P < 0.001
1
0.73 [0.60;0.87], P < 0.001
0.72 [0.60;0.88], P < 0.001
0.70 [0.58;0.85], P < 0.001
0.73 [0.63;0.93], P 0.008
Individuals with CVD
Continuous 0.999 [0.999; 0.999] 0.999 [0.999; 0.999] 0.999 [0.999; 0.999] 0.999 [0.999; 0.999]
Continuous per 500 MET min/week 0.987 [0.979; 0.994] 0.990 [0.982; 0.997] 0.991 [0.983;0.999] 0.993 [0.984;1.00]
P for linear trend 0.001 0.01 0.04 0.08
Quartiles
Inactive (n = 147)
Q1 1 to 1,912 (n = 643)
Q2 1,913 to 3,690 (n = 589)
Q3 3,690 to 7,257 (n = 660)
Q4 >7,527 (n = 454)
1
0.69 [0.54; 0.89], P 0.004
0.65 [0.51; 0.84], P< 0.001
0.62 [0.48; 0.84], P< 0.001
0.56 [0.43; 0.74], P< 0.001
1
0.71 [0.56; 0.91], P 0.008
0.68 [0.53; 0.89], P 0.003
0.62 [0.48; 0.80], P< 0.001
0.61 [0.47; 0.80], P< 0.001
1
0.80 [0.62; 1.03], P 0.09
0.82 [0.63; 1.06], P 0.13
0.74 [0.57; 0.95], P 0.02
0.70 [0.53; 0.93], P 0.01
1
0.79 [0.62; 1.02], P 0.07
0.81 [0.62; 1.05], P 0.11
0.74 [0.57; 0.96], P 0.02
0.72 [0.54; 0.94], P 0.02
Model 1 was adjusted for age and sex.
� Model 2 was additional adjusted for confounders: income, education, alcohol consumption, smoking behavior (pack years), nutrient intake (i.e., protein (g/day), fat (g/
day), carbohydrate (g/day)), kidney function, arrhythmia, hypothyroid, lung disease, osteoarthritis, and rheumatoid arthritis.
† Model 3 was further adjusted for mediators: glucose levels, total cholesterol, diastolic BP, systolic BP, BMI, and sleep.
BMI, body mass index; BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; CVRF, cardiovascular risk factor; HR, hazard ratio; MACE, major
adverse cardiovascular event; MET, metabolic equivalent of task.
https://doi.org/10.1371/journal.pmed.1003845.t002
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0.77], P< 0.001, and Q4 0.69 [95% CI 0.57 to 0.84], P< 0.001). By contrast, in participants
with CVD, only the third and fourth most active quartiles showed significant reductions in all-
cause mortality and MACE (HRs Q1 0.80 [95% CI 0.62 to 1.03], P = 0.09, Q2 0.82 [95% CI
0.63 to 1.06], P = 0.13, Q3 0.74 [95% CI 0.57 to 0.95], P = 0.02, and Q4 0.70 [95% CI 0.53 to
0.93], P = 0.01).
Accordingly, the relationship between MVPA and health outcomes differed between
healthy individuals and those with CVD (P for interaction: Q1 P = 0.39, Q2 P = 0.01, Q3
P = 0.20, and Q4 P = 0.11; Fig 2, Table 2). After further adjustment for additional covariates
(i.e., mediators; model 3), reductions in adverse outcomes persisted with increasing MVPA,
but many estimates were no longer statistically significant, especially in healthy individuals.
Repeating these analyses for secondary outcomes largely reinforced the relation between
MVPA and event rate (S2 and S3 Tables). Our sensitivity analyses (S4 Table) confirmed our
main analyses and indicated that reverse causation bias and age restriction did not substan-
tially change the results.
Dose–response relationship of total MVPA
Increasing MVPA levels reduced the risk in all groups (Fig 3). The shape of the dose–response
association was curvilinear for individuals with CVRF and healthy individuals, suggesting no
additional health benefits above a certain volume of PA. This finding contrasts to CVD
patients, who showed a linear dose–response association suggesting no maximal effect of PA
on health. The magnitude and shape of the dose–response relationship of total MVPA and the
primary outcome differed significantly between healthy individuals and those with CVD at the
Fig 2. Quartiles of total and domain-specific MVPA associated with all-cause mortality and MACE stratified on health status. HRs were adjusted for age, sex,
income, education, alcohol consumption, smoking behavior (pack years), nutrient intake (i.e., protein (g/day), fat (g/day), carbohydrate (g/day)), kidney function,
arrhythmia, hypothyroid, lung disease, osteoarthritis, and rheumatoid arthritis. Higher levels of MVPA were associated with significant MACE and mortality risk
reductions in all groups, but the effects are health status and domain dependent. CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular events;
MVPA, moderate to vigorous physical activity; PA, physical activity.
https://doi.org/10.1371/journal.pmed.1003845.g002
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first part (i.e., at lower MVPA levels) of the dose–response association (P for interaction: spline
1 = 0.004, spline 2 = 0.04, spline 3 = 0.08, and spline 4 = 0.21). Finally, different dose–response
associations were also found for education levels in healthy individuals (P value for interaction:
spline 1 = 0.21, spline 2 = 0.061, and spline 3 = 0.048). Healthy individuals with low education
had a U-shaped dose–response relationship as high MVPA volumes resulted in attenuated
health benefits (S2 Fig). Age and sex did not affect the dose–response association of MVPA.
Dose–response relationship of domain-specific MVPA
The amount of total MVPA is largely determined by leisure PA (Table 1). In line with total
MVPA, participation in leisure MVPA was associated with a progressive reduction in adverse
outcomes, with more leisure MVPA associated with greater reductions in all-cause mortality
and incident MACE in healthy individuals and those with CVRF (Figs 2 and 3, S5–S7 Tables).
However, leisure MVPA was not associated with all-cause mortality and MACE in those with
CVD. Associations between nonleisure MVPA and adverse outcomes were less consistent
(Figs 2 and 3, S8–S10 Tables). Risk estimates for nonleisure MVPA quartiles were<1 in
healthy individuals, but did not reach statistical significance. In individuals with CVRF, non-
leisure MVPA Q1 (HR 0.86 [95% CI 0.77; 0.97], P = 0.02) and Q2 (HR 0.84 [95% CI 0.74;
0.95], P = 0.006) were associated with a reduced event rate, but risk reductions were not pres-
ent in nonleisure MVPA Q3 and Q4. In individuals with CVD, only nonleisure MVPA Q2
(HR 0.76 [95% CI 0.62 to 0.93], P = 0.008) was associated with a lower event rate compared to
inactive individuals. The results for leisure or nonleisure MVPA and CVD-related mortality
Fig 3. Association between total and domain-specific MVPA and all-cause mortality and MACE stratified. HRs were adjusted for age, sex, income, education, alcohol
consumption, smoking behavior (pack years), nutrient intake (i.e., protein (g/day), fat (g/day), carbohydrate (g/day)), kidney function, arrhythmia, hypothyroid, lung
disease, osteoarthritis, and rheumatoid arthritis. Frequency is the number of individuals within a PA category (per 1,000 MET min/week). Higher levels of MVPA were
associated with significant MACE and mortality risk reductions in all groups, but the effects are health status and domain dependent. CI, confidence interval; HR, hazard
ratio; MACE, major adverse cardiovascular events; MVPA, moderate to vigorous physical activity; PA, physical activity.
https://doi.org/10.1371/journal.pmed.1003845.g003
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and MACE were comparable. The results for all-cause mortality were stronger for leisure
MVPA and weaker for nonleisure MVPA (S7 and S10 Tables). When we separated occupa-
tional MVPA from nonleisure MVPA, we found no associations between occupational MVPA
and the primary and secondary outcomes (Figs 2 and 3, S11–S13 Tables).
Discussion
It is widely acknowledged that regular PA is strongly associated with a reduced risk of non-
communicable diseases and mortality [1,2], but the influence of cardiovascular health status
on this association is less clear. We observed that greater amounts of total MVPA were associ-
ated with a lower risk of all-cause mortality and MACE in a curvilinear dose-dependent man-
ner in healthy individuals and those with CVRF, with benefits plateauing at high PA volumes.
By contrast, the dose–response curve of MVPA in individuals with CVD indicated a linear
association. The risk reductions were primarily derived from leisure MVPA, since health bene-
fits associated with nonleisure MVPA, including occupational MVPA, were largely insignifi-
cant. Our results suggest that the shape of the dose–response relationship between MVPA and
all-cause mortality and MACE is different for individuals with CVD compared to healthy indi-
viduals and those with CVRF.
Cardiovascular health status and MVPA benefits
The MVPA volume needed to achieve the maximal risk reduction was higher in CVD individ-
uals (i.e., Q4; HR 0.70) compared to healthy individuals (i.e., Q2; HR 0.71) and those with
CVRF (i.e., Q3; HR 0.64). These findings suggest that CVD patients need to perform more
MVPA to obtain similar health benefits as healthy and CVRF individuals, despite the magni-
tude of the risk reduction is comparable between healthy individuals and those with CVD.
Our findings reinforce observations from a large Korean study, in which PA-induced mortality
reductions differed for primary and secondary prevention [8]. The potential explanation for
why CVD patients have a different dose–response association for MVPA to reduce events is
currently not clear, but CVD patients may require greater exercise stimuli to alter CVRF or
their hemodynamic response to exercise [31] or experience an attenuated adaptations to exer-
cise due to CVD medications [32]. Alternatively, different pathophysiological processes,
altered by different amounts of MVPA, could lead to MACE and death in patients with estab-
lished CVD.
Individuals with CVRF had the largest risk reductions, which suggest that those with risk
factors benefit most from an active lifestyle. This may be explained by PA-induced risk factor
improvements such as increased HDL cholesterol [33] and reductions in body weight, BP [34],
glucose [35], triglycerides, and inflammatory markers [36], which are all known to reduce
CVD events. Furthermore, the optimal PA dose for maximal risk reduction was different for
the 3 subgroups: Q2 for the healthy, Q3 for those with CVRF, and Q4 for those with CVD.
These findings further emphasize that PA recommendations should not follow a “one-guide-
line-fits-all” approach, but underline the need for precision medicine in which PA prescription
may dependent, among other factors, on an individual’s cardiovascular health status.
There is debate as to whether the health benefits of PA disappear at high levels of PA [37],
especially in CVD patients [38]. We found no evidence of an upper PA limit above which
there is no further benefit in those with CVD, suggesting that more PA is better. By contrast,
reductions in adverse outcomes were no longer statistically significant at high PA volumes in
individuals with CVRF (Fig 3). This observation agrees with most [9–11,39], but not all [6,7],
previous studies. A potential explanation for the upper PA limit may be due to the transient
increased risk for sudden cardiac death during exercise [40] or the use of a single measure,
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which might induce nondifferential measurement error in regards to outcome ascertainment
[41].
Leisure versus nonleisure MVPA
Current PA guidelines [22] do not differentiate between leisure and nonleisure MVPA. A mul-
ticountry cohort study (including 168,916 participants) reported that both higher recreational
(i.e., leisure) and nonrecreational (i.e., nonleisure) PA were associated with lower mortality
and fewer CVD events [42]. By contrast, a meta-analysis of 17 studies (n = 193,696) indicated
that high volumes of occupational PA, a part of nonleisure PA, were associated with detrimen-
tal health consequences in men [13]. Looking at domain-specific PA, we observed that leisure
MVPA was associated with significant risk reductions in the healthy and CVRF groups,
whereas no significant effect was observed in the CVD group (Figs 2 and 3). Nonleisure
MVPA appeared only beneficial at low-to-moderate volumes in individuals with CVRF and
CVD and did not influence health outcomes at high volumes and in healthy individuals. Occu-
pational MVPA was not associated with health outcomes in our study. The underlying mecha-
nisms responsible for differences in health outcomes for MVPA spent in different domains
remain unclear. Some researchers suggest different physiological responses to occupational
PA, such as no improvements of cardiorespiratory fitness and increases in 24-hour heart rate,
BP, and inflammation [13,43]. Others argue that the detrimental association of occupational
PA is biased by inadequate classification of occupational demands and incomplete adjustment
for confounding factors [44]. To overcome incomplete adjustment, we have adjusted our
results for differences in education level, income, and lifestyle. Taken together, our results sug-
gest that the benefits of MVPA are domain specific, which urges future studies to further
explore this topic to ultimately improve PA prescription.
Strengths and limitations
Strengths of this study include the large population, outcome data based on national health sta-
tistics, comprehensive measurement of MVPA, and correction for important confounders.
Study limitations include (1) self-reported PA data, which may overestimate PA volume; how-
ever, overreporting generally underestimates the true effect of exercise on health outcomes
[45]. Furthermore, underlying health conditions (e.g., overweight, high BP, or reduced cardio-
respiratory fitness) could affect the way participants experienced the intensity of the PA that
they performed, which might affect the response to the questionnaire and thereby MET score
of the specific PA; (2) health status was based on questionnaires, but was cross-validated using
medication data ensuring that individuals with CVRF and CVD were classified correctly; (3)
the study design was observational, which is prone for residual confounding; (4) occupational
PA had little variance for the nonhealthy groups, which could weaken the association between
occupational PA and health outcomes; and (5) when hospital registry data were not available,
self-reported MACE were used instead. The date of self-reported MACE was based on the date
at which the participant filled in the follow-up questionnaire, which may slightly deviate from
the date at which the MACE occurred. Since we adjusted for the most common confounding
factors, we reduced the risks of residual confounding as much as possible. Finally, light inten-
sity PA was not assessed. Previous studies using device-based measures of PA showed that
light intensity PA was associated with mortality [46], suggesting that performing some PA is
better than performing none [22]. Especially in individuals with CVD, starting with light
intensity PA is a feasible way to increase the level of habitual PA.
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Conclusions
Higher levels of MVPA were associated with significant CVD and mortality risk reductions in
all groups, but benefits plateaued at high PA volumes in healthy individuals and those with
CVRF. Cardiovascular health status affected the dose–response association between PA and
MACE and all-cause mortality. Specifically, in individuals with CVD, larger volumes of
MVPA were linked to health benefits compared to healthy individuals and those with CVRF.
Healthy controls and individuals with CVRF demonstrated a curvilinear relationship, whereas
a linear association was found among individuals with CVD. Furthermore, we observed
important differences in risk reductions across different domains of MVPA. Leisure MVPA
was associated with the most health benefits, nonleisure MVPA with little health benefits, and
occupational MVPA with no health benefits. Outcomes from this study are useful to further
optimize PA recommendations, so that every individual, irrespective of cardiovascular health
status, can optimally benefit from a physically active lifestyle.
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